News archive

Read the latest news from the nanomedicine world.

Nanobiotix, the late clinical-stage Nanomedicine company and Platinum member of the ETPN has been rewarded during the ceremony 2018 of the CphI Awards on October 9 in Madrid, Spain.

  • Nanobiotix won Pharma Company of the Year
  • Laurent Lévy, CEO of Nanobiotix, won CEO of the year

About the Awards: The CPhI Pharma Awards were launched by CPhI in 2004 to provide recognition to pharmaceutical companies that turn inspiration into innovation. The CPhI Pharma Awards celebrate thinkers and creators breaking new ground in the industry and strongly advocate companies that are committed to driving the industry forward. With the support of leading pharma associations and media partners, the CPhI Pharma Awards have become the most prestigious awards in the Pharma industry.On its 15th edition, CPhI Pharma Awards will give recognition in 17 categories including the CEO of the Year and the Corporate Social Responsibility amongst others. The winners will be announced at the prestigious CPhI Pharma Awards Gala, taking place on the first evening of CPhI Worldwide 2018 in Madrid with attendance of over 350 guests.

About Nanobiotix: Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company’s Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.